HRP20110645T1 - Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina - Google Patents

Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina Download PDF

Info

Publication number: HRP20110645T1
Authority: HR; Croatia
Prior art keywords: compound; base; crystalline; crystalline base; salt
Prior art date: 2005-02-16

Application number

HR20110645T

Other languages

English (en)

Croatian (hr)

Inventor

Bang-Andersen Benny

Lopez De Diego Heidi

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-16

Filing date

2006-02-14

Publication date

2011-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110645(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-14 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2011-10-31 Publication of HRP20110645T1 publication Critical patent/HRP20110645T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

HR20110645T 2005-02-16 2006-02-14 Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina HRP20110645T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65341905P	2005-02-16	2005-02-16
DKPA200500239		2005-02-16
PCT/DK2006/000088 WO2006086986A1 (en)	2005-02-16	2006-02-14	Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (1)

Publication Number	Publication Date
HRP20110645T1 true HRP20110645T1 (hr)	2011-10-31

Family

ID=37908539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110645T HRP20110645T1 (hr)	2005-02-16	2006-02-14	Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina

Country Status (28)

Country	Link
US (2)	US7648991B2 (sr)
EP (1)	EP1853576B1 (sr)
JP (1)	JP5055135B2 (sr)
KR (1)	KR101386387B1 (sr)
CN (1)	CN101119983B (sr)
AR (1)	AR052909A1 (sr)
AT (1)	ATE515501T1 (sr)
AU (1)	AU2006215957B9 (sr)
BR (1)	BRPI0607436B8 (sr)
CA (1)	CA2597622C (sr)
CY (1)	CY1111857T1 (sr)
DK (1)	DK1853576T3 (sr)
EA (1)	EA017631B1 (sr)
ES (1)	ES2368786T3 (sr)
HR (1)	HRP20110645T1 (sr)
IL (1)	IL184551A (sr)
MX (1)	MX2007009980A (sr)
MY (1)	MY148683A (sr)
NO (1)	NO339863B1 (sr)
NZ (1)	NZ556397A (sr)
PL (1)	PL1853576T3 (sr)
PT (1)	PT1853576E (sr)
RS (1)	RS51944B (sr)
SI (1)	SI1853576T1 (sr)
TW (1)	TWI376373B (sr)
UA (1)	UA95901C2 (sr)
WO (1)	WO2006086986A1 (sr)
ZA (1)	ZA200705982B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1658277T3 (pl)	2003-08-18	2012-10-31	H Lundbeck As	Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI376373B (en)	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound
TWI453198B (zh) *	2005-02-16	2014-09-21	Lundbeck & Co As H	製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
CN102065861B (zh) *	2008-05-07	2013-10-16	H.隆德贝克有限公司	反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
CN102170884A (zh) *	2008-10-03	2011-08-31	H.隆德贝克有限公司	口服制剂
DK2720989T3 (en)	2011-06-20	2016-11-28	H Lundbeck As	Deuterated 1-piperazino-3-phenyl-indanes used to treat schizophrenia
WO2020089147A1 (en)	2018-10-29	2020-05-07	H. Lundbeck A/S	Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en)	2018-12-03	2020-06-11	H. Lundbeck A/S	Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4031216A (en)	1974-08-12	1977-06-21	Knoll A.G. Chemische Fabriken	3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en)	1980-02-29	1986-08-06	Kefalas As	Indane derivatives
DE3139970A1 (de)	1981-10-08	1983-04-28	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en)	1987-04-01	1991-06-25	Janssen Pharmaceutica N.V.	4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en)	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
HUT67665A (en)	1991-11-05	1995-04-28	Smithkline Beckman Corp	Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
CA2091204C (en)	1992-03-11	1997-04-08	Ronald J. Mattson	Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja)	1992-12-22	1994-07-05	Kotobuki Seiyaku Kk	ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
ES2108484T3 (es)	1993-11-30	1997-12-16	Pfizer	Procedimiento para la preparacion de una tetralona asimetrica.
CA2132411A1 (en)	1994-09-19	1996-03-20	Michael Trani	Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en)	1994-12-16	2002-09-24	Uop Llc	Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en)	1994-12-16	2002-06-25	Uop Llc	Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en)	1996-03-01	1998-09-15	Zeneca Limited	Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en)	1998-02-23	2001-07-31	Zymogenetics, Inc.	Piperazine derivatives for treating bone deficit conditions
ATE255555T1 (de)	1998-05-01	2003-12-15	Pfizer Prod Inc	Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
KR100605140B1 (ko)	1998-05-22	2006-07-28	싸이오스 인크	심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
DE19824470A1 (de)	1998-05-30	1999-12-02	Boehringer Ingelheim Pharma	Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
FR2786769B1 (fr)	1998-12-04	2002-10-25	Synthelabo	Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1059302A1 (en)	1999-06-08	2000-12-13	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitors
JP2000351773A (ja)	1999-06-08	2000-12-19	Yamanouchi Pharmaceut Co Ltd	フラン誘導体からなる医薬
AR031520A1 (es)	1999-06-11	2003-09-24	Vertex Pharma	Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en)	1999-06-21	2002-04-09	Agouron Pharmaceuticals, Inc.	Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (sr)	2000-01-04	2002-02-23	Sun Pharmaceutical Ind Ltd
PL1658277T3 (pl) *	2003-08-18	2012-10-31	H Lundbeck As	Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI453198B (zh)	2005-02-16	2014-09-21	Lundbeck & Co As H	製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2006086985A1 (en)	2005-02-16	2006-08-24	H. Lundbeck A/S	Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en)	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound

2006
- 2006-02-07 TW TW095103995A patent/TWI376373B/zh not_active IP Right Cessation
- 2006-02-14 ES ES06706059T patent/ES2368786T3/es not_active Expired - Lifetime
- 2006-02-14 AR ARP060100519A patent/AR052909A1/es unknown
- 2006-02-14 WO PCT/DK2006/000088 patent/WO2006086986A1/en not_active Ceased
- 2006-02-14 DK DK06706059.0T patent/DK1853576T3/da active
- 2006-02-14 KR KR1020077017725A patent/KR101386387B1/ko not_active Expired - Fee Related
- 2006-02-14 HR HR20110645T patent/HRP20110645T1/hr unknown
- 2006-02-14 BR BRPI0607436A patent/BRPI0607436B8/pt not_active IP Right Cessation
- 2006-02-14 CN CN200680005006.1A patent/CN101119983B/zh not_active Expired - Fee Related
- 2006-02-14 SI SI200631104T patent/SI1853576T1/sl unknown
- 2006-02-14 AT AT06706059T patent/ATE515501T1/de active
- 2006-02-14 MX MX2007009980A patent/MX2007009980A/es active IP Right Grant
- 2006-02-14 JP JP2007554426A patent/JP5055135B2/ja not_active Expired - Fee Related
- 2006-02-14 RS RS20110418A patent/RS51944B/sr unknown
- 2006-02-14 UA UAA200710266A patent/UA95901C2/ru unknown
- 2006-02-14 CA CA2597622A patent/CA2597622C/en not_active Expired - Fee Related
- 2006-02-14 US US11/816,394 patent/US7648991B2/en not_active Expired - Fee Related
- 2006-02-14 NZ NZ556397A patent/NZ556397A/en not_active IP Right Cessation
- 2006-02-14 PL PL06706059T patent/PL1853576T3/pl unknown
- 2006-02-14 PT PT06706059T patent/PT1853576E/pt unknown
- 2006-02-14 ZA ZA200705982A patent/ZA200705982B/xx unknown
- 2006-02-14 EA EA200701740A patent/EA017631B1/ru unknown
- 2006-02-14 AU AU2006215957A patent/AU2006215957B9/en not_active Ceased
- 2006-02-14 EP EP06706059A patent/EP1853576B1/en not_active Expired - Lifetime
- 2006-02-15 MY MYPI20060624A patent/MY148683A/en unknown
2007
- 2007-07-12 IL IL184551A patent/IL184551A/en active IP Right Grant
- 2007-09-12 NO NO20074639A patent/NO339863B1/no not_active IP Right Cessation
2009
- 2009-12-01 US US12/628,613 patent/US8450324B2/en not_active Expired - Fee Related
2011
- 2011-09-27 CY CY20111100928T patent/CY1111857T1/el unknown

Also Published As

Publication number	Publication date
MY148683A (en)	2013-05-31
ZA200705982B (en)	2009-06-24
AU2006215957B2 (en)	2011-09-29
KR101386387B1 (ko)	2014-04-25
HK1117525A1 (en)	2009-01-16
CN101119983A (zh)	2008-02-06
SI1853576T1 (sl)	2011-11-30
US20080153848A1 (en)	2008-06-26
AR052909A1 (es)	2007-04-11
PL1853576T3 (pl)	2011-12-30
JP5055135B2 (ja)	2012-10-24
NO20074639L (no)	2007-09-12
BRPI0607436A2 (pt)	2010-04-06
AU2006215957B9 (en)	2012-02-16
EA200701740A1 (ru)	2007-12-28
EP1853576B1 (en)	2011-07-06
US20100105699A1 (en)	2010-04-29
EP1853576A1 (en)	2007-11-14
AU2006215957A1 (en)	2006-08-24
BRPI0607436B1 (pt)	2020-10-06
CA2597622C (en)	2013-11-12
NZ556397A (en)	2010-06-25
KR20070103414A (ko)	2007-10-23
WO2006086986A1 (en)	2006-08-24
CN101119983B (zh)	2014-11-12
UA95901C2 (en)	2011-09-26
IL184551A0 (en)	2007-10-31
IL184551A (en)	2014-05-28
NO339863B1 (no)	2017-02-13
EA017631B1 (ru)	2013-02-28
ES2368786T3 (es)	2011-11-22
TW200640890A (en)	2006-12-01
ATE515501T1 (de)	2011-07-15
US8450324B2 (en)	2013-05-28
DK1853576T3 (da)	2011-09-26
PT1853576E (pt)	2011-09-28
TWI376373B (en)	2012-11-11
JP2008530040A (ja)	2008-08-07
CY1111857T1 (el)	2015-11-04
BRPI0607436B8 (pt)	2021-05-25
RS51944B (sr)	2012-02-29
US7648991B2 (en)	2010-01-19
MX2007009980A (es)	2007-09-26
CA2597622A1 (en)	2006-08-24

Publication	Publication Date	Title
ES2553968T3 (es)	2015-12-15	Moduladores del receptor NMDA y sus usos
HRP20121010T1 (hr)	2013-01-31	Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin
CN102285984B (zh)	2012-10-10	(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
CN101798270B (zh)	2013-04-17	一种3-氨基-1-金刚烷醇的制备方法
CN113336735B (zh)	2022-09-30	一种尿石素类化合物、制备方法、药物组合物及用途
IL255433B2 (en)	2023-07-01	(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6130071B2 (ja)	2017-05-17	１，７−ナフチリジン誘導体
HRP20110645T1 (hr)	2011-10-31	Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina
AU2004272337B2 (en)	2008-02-14	Novel crystalline polymorphs of clopidogrel
WO2016166078A1 (en)	2016-10-20	Pyridopyrimidinones and their use as nmda receptor modulators
TW408117B (en)	2000-10-11	Use of N-substituted phenothiazines
JP2023015178A (ja)	2023-01-31	インドリノベンゾジアゼピン誘導体の調製方法
NZ523174A (en)	2004-06-25	New substituted phthalides, a process for their preparation and pharmaceutical compositions containing them
JP2022065012A (ja)	2022-04-26	Ｄ－アミノ酸オキシダーゼ（ｄａａｏ）阻害剤としての新規な置換ベンゾイミダゾール誘導体
RS56659B1 (sr)	2018-03-30	Intermedijeri agomelatina i postupak njihove izrade
US7425627B2 (en)	2008-09-16	Methods of synthesizing olanzapine
WO2008093142A1 (en)	2008-08-07	Process for the preparation of o-desmethyl venlafaxine
CN102731326A (zh)	2012-10-17	一种合成（s）-2-氨基-5-甲氧基-1,2,3,4-四氢萘盐酸盐的方法
JP7414814B2 (ja)	2024-01-16	（－）－シベンゾリンコハク酸塩の新規な製造工程
CN102083837B (zh)	2013-09-18	硫酸氢氯吡格雷晶型i的制备方法
JP2008509105A (ja)	2008-03-27	キヌレニン−アミノトランスフェラーゼ阻害剤として有用な４−スルホニル−置換ベンゾイルアラニン誘導体
CN103360241B (zh)	2016-08-03	光学纯5-氧代三环[2，2，1，02，6]庚烷-3-羧酸的制备方法
CN102417497B (zh)	2014-04-30	光学活性1-茚酮-3-乙酸类化合物的制备方法
CN120289357A (zh)	2025-07-11	联苯类化合物、其制备方法、中间体、药物组合物和应用
CN102491956A (zh)	2012-06-13	左旋盐酸司他斯汀及其制备方法